U.S. stock insider trading | ProMIS Neurosciences disclosed one company insider transaction on March 6, including transaction details

On March 6, 2026, ProMIS Neurosciences (PMN) disclosed one instance of company insider trading activity. On March 5, 2026, Director Williams Eugene bought 2,000 shares.

【Recent Insider Trading】

【Company Profile】

ProMIS Neurosciences Inc. was incorporated on January 23, 2004, under the Canada Business Corporations Act, and is located at 1920 Yonge Street, Central Toronto, Ontario. The company is applying its patented technology platform to build combinations of antibody therapies, therapeutic vaccines, and other antibody-based treatment approaches for neurodegenerative diseases and other misfolded protein disorders (including Alzheimer’s disease, multiple system atrophy, and amyotrophic lateral sclerosis). The company also plans to study other synucleinopathies, including Parkinson’s disease and Lewy body dementia, frontotemporal dementia, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. These diseases share a common biological cause—misfolded proteins, which would otherwise perform normal functions, become toxic, and kill neurons, thereby leading to disease. ProMIS’s technology platform is an example of advances in drug discovery achieved through computational power, computer-aided discovery, and artificial intelligence.